Developer docs
API playgroundTry for free, no card

Search company profiles

Actify Neurotherapies

Full company profile

uuid0032bng

Namestring
Actify Neurotherapies
Legal namestring
TC MSO, Inc.
Websiteurl
actifyneuro.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Actify Neurotherapies, operating under legal entity TC MSO, Inc., is a Princeton, NJ-based private healthcare network founded in 2011 that operates a multi-site clinical service delivering intravenous (IV) ketamine infusion therapy. The company treats six mental health and pain conditions — major depression (including postpartum), PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes — positioning ketamine as a rapid-acting alternative for patients who have not responded to traditional daily antidepressant medications.

The business is built around a network of 10 clinic locations spread across the Mid-Atlantic, Northeast, Southeast, West, and South regions of the United States, staffed by approximately 10 board-certified physicians and an operational team of 11–50 employees. Actify has administered 30,000+ cumulative infusions to 2,000+ patients. The underlying technology is a standard IV ketamine infusion protocol; no proprietary compound, device, or digital platform is documented.

Revenue is generated on a per-session basis from patients who pay out of pocket, with intake handled through a direct-to-consumer funnel (free 15-minute phone consultation, website contact form) and supplemented by clinician referrals. Coordination specialists route patients to their preferred clinic location, and treatments are administered in-person. No insurance, enterprise, or payor agreements are documented, and no funding rounds, M&A activity, or parent company relationships have been disclosed.

Short descriptiontext

Actify Neurotherapies is a Princeton, NJ-based private clinic network founded in 2011 that delivers IV ketamine infusion therapy across 10 US locations to patients with treatment-resistant depression, PTSD, bipolar depression, OCD, anxiety, and chronic pain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersPrinceton, United States
HQ citystring
Princeton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices10 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
ketamine infusion therapy, mental health treatment, treatment-resistant depression, IV ketamine clinics, psychiatric infusion services
Industry2 codes
PRIMARYHLAFACAG
Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs)
Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
NAICS code2 codes
  • Outpatient Mental Health and Substance Abuse Centers62142
  • Offices of Physicians, Mental Health Specialists621112
SIC code2 codes
  • Services-Specialty Outpatient Facilities, Nec8093
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Mental Health Infusion Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Ketamine Infusion Treatment Services
TypeOne Time License
Description

Revenue generated from providing intravenous ketamine infusion therapy sessions to patients. Patients pay per treatment session. The company offers treatment for multiple mental health conditions including major depression, PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes.

actifyneuro.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain
Pricing details1 tier
1Treatment session pricing
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Specific treatment pricing not publicly disclosed on the website.

actifyneuro.com
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Actify Neurotherapies operates a network of 10 ketamine infusion therapy centers across the United States that administer intravenous ketamine treatments to patients with treatment-resistant mental health conditions. Treatments are delivered by qualified physicians and address major depression (including postpartum), PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes. Patients access care through free phone consultations, online contact forms, and provider referrals, and pay per treatment session at their preferred clinic location.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Rapid symptom relief within hours of treatment (vs. weeks for traditional antidepressants)
+1 more record
Product overview1 text field

Actify Neurotherapies offers a single core service: Ketamine Infusion Therapy. The company operates a network of 10+ treatment centers across the United States providing intravenous ketamine treatments for treatment-resistant mental health conditions. The therapy is positioned as an alternative to daily medications for patients who have not responded to traditional treatments. The company facilitates initial consultations, coordinates treatment scheduling across locations, and provides ongoing care through its network of medical doctors.

Product and service1 record
1Ketamine Infusion Therapy
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large digital mental health platform offering medication management and therapy for depression and anxiety. Comparable in target patient demographic and mental-health focus, but operates via telehealth and prescription rather than in-clinic infusion.

2Nue Life
TypeDirect peer
Description

Ketamine therapy provider combining infusion clinics with at-home treatment programs for depression, PTSD, and anxiety. Directly comparable to Actify in indication set and patient demographic, with overlapping emphasis on treatment-resistant populations.

TypeDirect peer
Description

National network of ketamine infusion clinics treating depression, PTSD, anxiety, and chronic pain. Direct comparable in clinic-network model, multi-condition offering, and geographic distribution strategy.

TypeDirect peer
Description

Specialty outpatient clinic offering ketamine and Spravato infusions for depression, anxiety, and PTSD. Closely comparable in service mix, multi-condition scope, and direct-to-consumer patient acquisition.

TypeEmerging player
Description

Employer-sponsored mental health platform providing therapy, medication, and care navigation. Targets a similar mental-health patient population but through a virtual-first, benefits-funded model rather than clinic-based ketamine infusion.

6Better U
TypeDirect peer
Description

Outpatient ketamine and Spravato clinic operator serving treatment-resistant mental health patients. Comparable in service offering and patient target, though typically with smaller clinic footprints than Actify.

7Spravato (Janssen / Johnson & Johnson)
TypeBroad incumbent
Description

FDA-approved esketamine nasal spray for treatment-resistant depression, marketed by Janssen. The principal pharmaceutical incumbent addressing Actify's core depression patient population through a regulated, insurance-covered alternative that competes for the same clinical use case.

8Field Trip Health
TypeDirect peer
Description

Was a direct competitor operating ketamine-assisted psychotherapy clinics in major US and Canadian cities before winding down US clinic operations. Operated the same multi-clinic, ketamine-for-mental-health model as Actify and remains the closest precedent for clinic-network scaling in this category.

TypeDirect peer
Description

Telehealth-enabled platform connecting patients with clinicians providing ketamine and Spravato treatment. Comparable patient population and treatment offerings, differing in delivery modality (remote prescriber network vs. owned clinics).

TypeDirect peer
Description

Direct competitor offering ketamine therapy for mental health conditions. While Mindbloom emphasizes at-home sublingual ketamine versus Actify's in-clinic IV, both target the same treatment-resistant patient population with the same active drug and similar outcome messaging.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment6 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Actify Neurotherapies

Mental Health Infusion Servicesactifyneuro.com

Actify Neurotherapies is a Princeton, NJ-based private clinic network founded in 2011 that delivers IV ketamine infusion therapy across 10 US locations to patients with treatment-resistant depression, PTSD, bipolar depression, OCD, anxiety, and chronic pain.

What Actify Neurotherapies does

Actify Neurotherapies, operating under legal entity TC MSO, Inc., is a Princeton, NJ-based private healthcare network founded in 2011 that operates a multi-site clinical service delivering intravenous (IV) ketamine infusion therapy. The company treats six mental health and pain conditions — major depression (including postpartum), PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes — positioning ketamine as a rapid-acting alternative for patients who have not responded to traditional daily antidepressant medications.

The business is built around a network of 10 clinic locations spread across the Mid-Atlantic, Northeast, Southeast, West, and South regions of the United States, staffed by approximately 10 board-certified physicians and an operational team of 11–50 employees. Actify has administered 30,000+ cumulative infusions to 2,000+ patients. The underlying technology is a standard IV ketamine infusion protocol; no proprietary compound, device, or digital platform is documented.

Revenue is generated on a per-session basis from patients who pay out of pocket, with intake handled through a direct-to-consumer funnel (free 15-minute phone consultation, website contact form) and supplemented by clinician referrals. Coordination specialists route patients to their preferred clinic location, and treatments are administered in-person. No insurance, enterprise, or payor agreements are documented, and no funding rounds, M&A activity, or parent company relationships have been disclosed.

Actify Neurotherapies firmographics

Firmographics
Name
Actify Neurotherapies
Legal name
TC MSO, Inc.
Website
https://actifyneuro.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
11–50 employees
Short description
Actify Neurotherapies is a Princeton, NJ-based private clinic network founded in 2011 that delivers IV ketamine infusion therapy across 10 US locations to patients with treatment-resistant depression, PTSD, bipolar depression, OCD, anxiety, and chronic pain.
Ownership category
akta.pro rank

Actify Neurotherapies industry classification

Industry
Product category
Mental Health Infusion Services
NAICS
Outpatient Mental Health and Substance Abuse Centers (62142), Offices of Physicians, Mental Health Specialists (621112)
SIC
Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)
akta.pro industry
PRIMARYHLAFACAG
Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs)
Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)

Keywords

  • Ketamine infusion therapy
  • Mental health treatment
  • Treatment-resistant depression
  • IV ketamine clinics
  • Psychiatric infusion services

Where Actify Neurotherapies is headquartered

Location

Headquarters

HQ city
Princeton
HQ country
United States
HQ region
North America

Offices10 records

Markets served

Actify Neurotherapies business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

  1. Ketamine Infusion Treatment Services: Revenue generated from providing intravenous ketamine infusion therapy sessions to patients. Patients pay per treatment session. The company offers treatment for multiple mental health conditions including major depression, PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goTreatment session pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Actify Neurotherapies product offering

Product offering

Core offering

Actify Neurotherapies operates a network of 10 ketamine infusion therapy centers across the United States that administer intravenous ketamine treatments to patients with treatment-resistant mental health conditions. Treatments are delivered by qualified physicians and address major depression (including postpartum), PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes. Patients access care through free phone consultations, online contact forms, and provider referrals, and pay per treatment session at their preferred clinic location.

Product overview

Actify Neurotherapies offers a single core service: Ketamine Infusion Therapy. The company operates a network of 10+ treatment centers across the United States providing intravenous ketamine treatments for treatment-resistant mental health conditions. The therapy is positioned as an alternative to daily medications for patients who have not responded to traditional treatments. The company facilitates initial consultations, coordinates treatment scheduling across locations, and provides ongoing care through its network of medical doctors.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ketamine Infusion Therapy

Quantifiable outcome

  • Rapid symptom relief within hours of treatment (vs. weeks for traditional antidepressants)
  • +1 more outcomes

Companies that use Actify Neurotherapies

Customer profile

Segments6 records

Ideal customer profiles1 record

Actify Neurotherapies technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Actify Neurotherapies partnerships and signals

Strategic signal

Scale indicators3 records

Recent moves5 records

Expansion highlights4 records

Actify Neurotherapies competitors and assessment

Company assessment

Broad incumbents

  • Cerebral: Large digital mental health platform offering medication management and therapy for depression and anxiety. Comparable in target patient demographic and mental-health focus, but operates via telehealth and prescription rather than in-clinic infusion.
  • Spravato (Janssen / Johnson & Johnson): FDA-approved esketamine nasal spray for treatment-resistant depression, marketed by Janssen. The principal pharmaceutical incumbent addressing Actify's core depression patient population through a regulated, insurance-covered alternative that competes for the same clinical use case.

Direct peers

  • Nue Life: Ketamine therapy provider combining infusion clinics with at-home treatment programs for depression, PTSD, and anxiety. Directly comparable to Actify in indication set and patient demographic, with overlapping emphasis on treatment-resistant populations.
  • Ketamine Wellness Centers: National network of ketamine infusion clinics treating depression, PTSD, anxiety, and chronic pain. Direct comparable in clinic-network model, multi-condition offering, and geographic distribution strategy.
  • Klarity Clinic: Specialty outpatient clinic offering ketamine and Spravato infusions for depression, anxiety, and PTSD. Closely comparable in service mix, multi-condition scope, and direct-to-consumer patient acquisition.
  • Better U: Outpatient ketamine and Spravato clinic operator serving treatment-resistant mental health patients. Comparable in service offering and patient target, though typically with smaller clinic footprints than Actify.
  • Field Trip Health: Was a direct competitor operating ketamine-assisted psychotherapy clinics in major US and Canadian cities before winding down US clinic operations. Operated the same multi-clinic, ketamine-for-mental-health model as Actify and remains the closest precedent for clinic-network scaling in this category.
  • Journey Clinical: Telehealth-enabled platform connecting patients with clinicians providing ketamine and Spravato treatment. Comparable patient population and treatment offerings, differing in delivery modality (remote prescriber network vs. owned clinics).
  • Mindbloom: Direct competitor offering ketamine therapy for mental health conditions. While Mindbloom emphasizes at-home sublingual ketamine versus Actify's in-clinic IV, both target the same treatment-resistant patient population with the same active drug and similar outcome messaging.

Emerging players

  • Spring Health: Employer-sponsored mental health platform providing therapy, medication, and care navigation. Targets a similar mental-health patient population but through a virtual-first, benefits-funded model rather than clinic-based ketamine infusion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Actify Neurotherapies social profiles

Digital presence

Actify Neurotherapies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Actify Neurotherapies leadership team

Management profile

Number of profiles

Profiles17 records

Actify Neurotherapies funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Actify Neurotherapies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Actify Neurotherapies

What does Actify Neurotherapies do?

Actify Neurotherapies operates a network of 10 ketamine infusion therapy centers across the United States that administer intravenous ketamine treatments to patients with treatment-resistant mental health conditions. Treatments are delivered by qualified physicians and address major depression (including postpartum), PTSD, bipolar depression, OCD, severe anxiety, and fibromyalgia/pain syndromes. Patients access care through free phone consultations, online contact forms, and provider referrals, and pay per treatment session at their preferred clinic location.

Is Actify Neurotherapies a public or private company?

Actify Neurotherapies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Actify Neurotherapies founded?

Actify Neurotherapies was founded in 2011. It employs 11 to 50 people.

Where is Actify Neurotherapies based?

Actify Neurotherapies is headquartered in Princeton, United States, in the North America region.

How does Actify Neurotherapies make money?

One revenue line is on record: ketamine Infusion Treatment Services.

Who are Actify Neurotherapies's main competitors?

Broad incumbents on record are Cerebral and Spravato (Janssen / Johnson & Johnson). Direct peers are Nue Life, Ketamine Wellness Centers, Klarity Clinic, Better U, Field Trip Health, Journey Clinical and Mindbloom. Spring Health is listed as an emerging player.

Does Actify Neurotherapies have an API?

No public API is recorded for Actify Neurotherapies.

What industry is Actify Neurotherapies in?

Actify Neurotherapies's product category is Mental Health Infusion Services. Its primary akta.pro industry code is HLAFACAG, Medication-Assisted Treatment (MAT) & Opioid Treatment Programs (OTPs), with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain). Its NAICS code is 62142 and its SIC code is 8093.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
CompasspathwaysChief Patient OfficerCompass Pathways has appointed Dr. Steve Levine as its Chief Patient Officer to lead efforts in enabling broad and equitable access to the company's psychedelic treatments. Dr. Levine brings over two decades of experience in psychiatry, having previously founded Actify Neurotherapies, the first ketamine clinics in the United States.PR NewswireActify Neurotherapies Announces Launch of SPRAVATO™ Pilot ProgramActify Neurotherapies announced the launch of a pilot program to offer SPRAVATO™, an FDA-approved esketamine nasal spray for treatment-resistant depression, at three of its northeast treatment centers. The company plans to expand the program to all nine of its facilities nationwide by the end of 2019. SPRAVATO™, manufactured by Janssen Pharmaceuticals, represents the first new FDA-approved medication for depression in decades and has shown efficacy in easing depression symptoms within hours when taken with oral antidepressants under medical supervision.Business InsiderA handful of clinics is embracing a 'party drug' that could be a rapid-fire depression treatment — we got a look insideActify Neurotherapies offers 45-minute ketamine infusions for severe depression and anxiety, with a single infusion costing $650 and insurance not covering it. A recent study found patients on ketamine reported depression symptoms 50% less frequently than those on other pain medications. The FDA has not yet approved ketamine for depression treatment.